
Opinion|Videos|April 6, 2026
Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, outline the role of ctDNA in guiding treatment decisions.
Advertisement
Episodes in this series

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, evaluate the clinical utility of circulating tumor DNA (ctDNA) in EGFR-mutant NSCLC. They discuss whether baseline ctDNA testing should be standard, and how ctDNA positivity and clearance may serve as prognostic and predictive biomarkers. The conversation highlights how ctDNA results can support, but not solely determine, decisions around treatment intensification.
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

